Effect of Dialysis Techniques on Blood Pressure and Cardiac Function During Dialysis (HOLLANT)

November 28, 2021 updated by: M.P.C. Grooteman, Amsterdam UMC, location VUmc

Effect of High-volume Online hemodiafiLtration on Intra-diaLytic hemodynAmic (iN)sTability and Cardiac Function in Chronic Hemodialysis Patients (the HOLLANT Study)

Online hemodiafiltration confers a reduced mortality risk. However, it is not clear why HDF improved survival. To gain more insight in this issue, the effect of 4 dialysis techniques (differing in dialysate temperature and the absence/presence of convective clearance) on intradialytic hemodynamic stability and cardiac function will be investigated in a prospective cross over trial.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Despite the use of high permeable dialyzers, which combine diffusive with convective clearance, the clinical outcome of hemodialysis (HD) patients remains poor. In post-dilution online hemodiafiltration (denoted further on as HDF) diffusive clearance is similar to HD, while the amount of convective transport is considerable increased. Recently, 4 randomized controlled trails have been published which compared HD with HDF. Although the results of the individual studies were inconclusive, a recent meta-analysis, using individual patient data of these studies, showed a superior outcome for patients treated with HDF. The largest mortality reduction was obtained in patients receiving the highest convection volume (high-volume HDF [HV-HDF] >23 L/1.73 m2/session): all-cause mortality [22% (95 % confidence interval [CI] 2-38)], cardiovascular disease (CVD) mortality [31% (95 % CI 0-53)].

It is far from clear, however, why (HV)HDF is associated with an improved survival. Both long term and short term effects may be involved. With respect to the latter, the intra-dialytic removal of middle molecular weight (MMW) uremic retention products and a superior bio-incompatibility (BI) profile may play a role. In addition, treatment with HDF may induce less intra-dialytic hypotension (IDH) and less tissue injury. Enhanced removal of the MMW substance FGF23 may reduce the intra-dialytic acute phase reaction (APR), which is regarded a chief element of HD-induced BI. Other key components which may contribute to IDH and are supposed to be alleviated by HDF, include dialysis-induced hypoxia and intra-dialytic extracellular vesicle release. Patho-physiologically, IDH depends both on a decline in the circulating blood volume and an impaired response to hypovolaemia. As a result, venous return, cardiac output and peripheral vascular resistance are impaired. Since IDH is reduced by HD with cool dialysate (C-HD), thermal factors may play an important role.

Microcirculatory dysfunction is a prominent feature of HD patients. Since IDH occurs in 20-30% of the sessions, any interference with an already abnormal perfusion may further deteriorate the structure and function of vital organs, such as the brain, gut and heart. HD-associated cardiomyopathy, which is considered a model of repetitive organ ischemia-reperfusion injury, is superimposed on the cardiac changes resulting from the various inflammatory and metabolic derangements of pre-dialysis kidney disease. As measured by imaging techniques and biomarkers, HD induces a fall in cardiac perfusion and elicits tissue injury. While cardiac MRI is considered the reference method for LV quantification, intra-dialytic measurements can only be obtained in stable patients who can be safely transferred to the radiology department. Echocardiography, though, can be performed in all individuals at the bed-side, including hypotension-prone patients. Because of its superiority over standard echocardiography, especially with respect to diastolic (dys)function, speckle tracking echocardiography will be used in the present study.

As mentioned, the effect on long term survival is especially prominent when HV-HDF is applied. Theoretically, HV-HDF is also the preferred treatment to circumvent dialysis-induced IDH, and hence, to alleviate the repetitive intra-dialytic tissue damage. Therefore, the following hypotheses will be tested:

  1. intra-dialytic hemodynamic stability is better preserved during HV-HDF as compared to standard (S)-HD, C-HD and low volume (LV)-HDF;
  2. mainly as a result of a better intra-dialytic hemodynamic stability, the severity of organ injury, especially the heart, is least evident during HV-HDF;
  3. the mechanism of a better preserved intra-dialytic hemodynamic stability during HV-HDF depends on its superior thermal balance and/or bio-incompatibility, clearance of MMW substances, or a combination of these items.

Worldwide, however, (HV)HDF is only limited available. Since intradialytic hemodynamic instability may contribute substantially to the poor clinical prospects of end-stage-kidney-disease (ESKD) patients, these individuals may benefit from each maneuver that minimizes the number and severity of intradialytic hypotensive episodes. Therefore, the question which of the comparator treatments [(S)-HD, C-HD and LV-HDF] has the best intradialytic hemodynamic stability, appears relevant as well.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Amstelveen, Netherlands, 1186 AM
        • Niercentrum aan de Amstel
      • Amsterdam, Netherlands
        • VUmc
    • Utrecht
      • Nieuwegein, Utrecht, Netherlands, 3435 CM
        • St Antonius Ziekenhuis

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • treatment with HD or HDF 3 x per week during at least 4 hours for at least 2 months
  • ability to understand study procedures
  • willingness to provide informed consent
  • single pool Kt/V urea (spKt/Vurea) ≥ 1.2
  • achievement of blood flow of ≥360 ml/min and/or convection volume of >23 Liter per treatment during the run-in phase

Exclusion Criteria:

  • - current age < 18 years
  • severe incompliance to dialysis procedure and accompanying prescriptions, especially frequency and duration of dialysis treatment
  • life expectancy < 3 months
  • participation in another clinical intervention trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: standard hemodialysis
prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 0 Liters (L)
hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
ACTIVE_COMPARATOR: cool hemodialysis
prescription of dialysate temperature: 35.5 degrees celsius prescription of convection volume: 0 L
hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
ACTIVE_COMPARATOR: low volume hemodiafiltration
prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
ACTIVE_COMPARATOR: high volume hemodiafiltration
prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
intradialytic hypotension
Time Frame: up to 4 hours (= one dialysis treatment); assessed during 3 treatments on each modality
nadir in systolic blood pressure (SBP) of 90 mmHg for patient with predialysis SBP <160mmHg and a nadir of 100 mmHg for patients with predialysis SBP ≥160 mmHg during treatment (blood pressure will be measured before and every 15 minutes after the start of dialysis during the treatment)
up to 4 hours (= one dialysis treatment); assessed during 3 treatments on each modality

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
diastolic dysfunction during treatment
Time Frame: up to 4 hours (= one dialysis treatment); assessed during 1 treatment on each modality
speckle tracking echocardiography will be performed before, after 60 minutes of dialysis and after and after 3,5 hours
up to 4 hours (= one dialysis treatment); assessed during 1 treatment on each modality

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
systolic blood pressure
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
change in systolic blood pressure (mmHg)
up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
diastolic blood pressure
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
change in diastolic blood pressure (mmHg)
up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
mean arterial blood pressure
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
change in mean arterial blood pressure (mmHg)
up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
pulse pressure
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
change in pulse pressure (systolic - diastolic blood pressure; mmHg)
up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
beat-to-beat blood pressure
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
change in beat-to-beat blood pressure (finger cuff; mmHg)
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
heart rate
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
change in heart rate (finger cuff assessment)
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
stroke volume
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
change in stroke volume (finger cuff assessment)
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
cardiac output
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
change in cardiac output (finger cuff assessment)
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
total peripheral resistance
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
change in total peripheral resistance (finger cuff assessment)
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
number of sessions with reached target dry weight
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
number of sessions with reached target dry weight (kg)
up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
relative blood volume
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 2 treatments on each modality
relative blood volume (%) during dialysis treatment
up to 4 hours(= one dialysis treatment); assessed during 2 treatments on each modality
oxygen saturation
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 2 treatments on each modality
oxygen saturation in the arterial line of the extracorporeal system (%) during dialysis treatment; patients with central venous catheters and fistulas/grafts will be analyzed separately
up to 4 hours(= one dialysis treatment); assessed during 2 treatments on each modality
oxygen partial pressure (pO2)
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
pO2 in the arterial line of the extracorporeal system (mmHg or kiloPascal [kPa], assessed by a point of care device) during dialysis treatment; patients with central venous catheters and fistulas/grafts will be analyzed separately
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
change in creatine kinase (CK)-MB
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
marker of cardiac damage, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
change in bacterial DNA in blood
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
marker of gut ischemia, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
change in soluble CD14
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
marker of gut ischemia, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
change in extracellular vesicles (EVs)
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
marker of endothelial damage, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
change in soluble intercellular adhesion molecule-1 (s-ICAM-1)
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
marker of endothelial damage, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
change in high sensitivity C-reactive protein (hs-CRP)
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
marker of inflammation, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
change in interleukin-6 (IL-6)
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
marker of inflammation, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
change in fibroblast growth factor-23 (FGF-23)
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
marker of inflammation/mineral bone disease, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 1, 2018

Primary Completion (ACTUAL)

February 15, 2021

Study Completion (ACTUAL)

February 15, 2021

Study Registration Dates

First Submitted

May 23, 2017

First Submitted That Met QC Criteria

August 9, 2017

First Posted (ACTUAL)

August 15, 2017

Study Record Updates

Last Update Posted (ACTUAL)

November 30, 2021

Last Update Submitted That Met QC Criteria

November 28, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • ABR 61210

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hemodialysis

Clinical Trials on cool hemodialysis

Search Similar Trials